1. Beigel JH, et al. Remdesivir for the treatment of Covid-19 – Preliminary report. N Engl J Med publoished online May 22, 2020; doi.10.1056/NEJMoa2007764.
2. Boulware DR, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med published online June 3, 2020; doi: 10.1056/NEJMoa2016638.
3. Cao B, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020;382:1787–99.
4. Carfi A, et al. Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA published online July 9, 2020; doi: 10.1001/jama.2020.12603.
5. Fotuhi M, et al. Neurobiology of COVID-19. J Alzheimers Dis 2020;76:3–19.
6. Geleris J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020;382:2411–8.
7. Grein J, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382:2327–36.
8. Guaraldi G, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol published online June 24, 2020; doi: https://doi.org/10.1016/S2665-9913(20)30173-9 .
9. Hung IF-N, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet published online May 8, 2020; doi: https://doi.org/10.1016/S0140-6736(20)31042-4 .
10. Jackson LA, et al. An mRNA vaccine against SARS-CoV-2 – Preliminary report. N Engl J Med published online July 14, 2020; doi: 10.1056/NEJMoa2022483 .
11. Kewan T, et al. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. EClinicalMedicine published online June 20, 2020; doi: https://doi.org/10.1016/j.eclinm.2020.100418.
12. Lechien JR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020;277:2251–61.
13. Mahevas M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. 2020; doi: https://doi.org/10.1101/2020.04.10.20060699 .
14. Mao L, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:683–90.
15. Recovery Collaborative Group, Horby P, et al. Dexamethasone in hospitalized patients with Covid-19 – Preliminary report. N Engl J Med published online July 17, 2020; doi: 10.1056/NEJMoa021436.
16. Rosenberg ES, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020;323:2493–502.
17. Tang W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:m1849.
18. Varatharaj A, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020; doi: https://doi.org/10.1016/S2215-0366(20)30287-X .
19. Wang Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569–78.
20. Williamson EJ, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature 2020; https://doi.org/10.1038/s41586-020-2521-4.
21. Yaghi S, et al. SARS-CoV-2 and stroke in a New York healthcare system. Stroke 2020;51:2002–11.
22. Zhu FC, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020;395:1845–54.